Literature DB >> 25778840

Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.

Pankaj Sharma1, Swathi Chinaranagari1, Jaideep Chaudhary2.   

Abstract

The four known ID proteins (ID1-4, Inhibitor of Differentiation) share a homologous helix loop helix (HLH) domain and act as dominant negative regulators of basic-HLH transcription factors. ID proteins also interact with many non-bHLH proteins in complex networks. The expression of ID proteins is increasingly observed in many cancers. Whereas ID-1, ID-2 and ID-3, are generally considered as tumor promoters, ID4 on the contrary has emerged as a tumor suppressor. In this study we demonstrate that ID4 heterodimerizes with ID-1, -2 and -3 and promote bHLH DNA binding, essentially acting as an inhibitor of inhibitors of differentiation proteins. Interaction of ID4 was observed with ID1, ID2 and ID3 that was dependent on intact HLH domain of ID4. Interaction with bHLH protein E47 required almost 3 fold higher concentration of ID4 as compared to ID1. Furthermore, inhibition of E47 DNA binding by ID1 was restored by ID4 in an EMSA binding assay. ID4 and ID1 were also colocalized in prostate cancer cell line LNCaP. The alpha helix forming alanine stretch N-terminal, unique to HLH ID4 domain was required for optimum interaction. Ectopic expression of ID4 in DU145 prostate cancer line promoted E47 dependent expression of CDKNI p21. Thus counteracting the biological activities of ID-1, -2 and -3 by forming inactive heterodimers appears to be a novel mechanism of action of ID4. These results could have far reaching consequences in developing strategies to target ID proteins for cancer therapy and understanding biologically relevant ID-interactions.
Copyright © 2015 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Cancer; DNA-Protein interaction; ID4; Protein–protein interaction; Tumor suppressor gene

Mesh:

Substances:

Year:  2015        PMID: 25778840      PMCID: PMC4402281          DOI: 10.1016/j.biochi.2015.03.006

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  87 in total

1.  Expression of the dominant-negative regulator Id4 is induced during adipocyte differentiation.

Authors:  H Chen; Y C Weng; G C Schatteman; L Sanders; R J Christy; B A Christy
Journal:  Biochem Biophys Res Commun       Date:  1999-03-24       Impact factor: 3.575

2.  Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.

Authors:  Anna Lasorella; Judith Stegmüller; Daniele Guardavaccaro; Guangchao Liu; Maria S Carro; Gerson Rothschild; Luis de la Torre-Ubieta; Michele Pagano; Azad Bonni; Antonio Iavarone
Journal:  Nature       Date:  2006-06-28       Impact factor: 49.962

3.  Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.

Authors:  A Dahlman; A Edsjö; C Halldén; J L Persson; S W Fine; H Lilja; W Gerald; A Bjartell
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-03       Impact factor: 5.554

4.  The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

Authors:  V Riechmann; I van Crüchten; F Sablitzky
Journal:  Nucleic Acids Res       Date:  1994-03-11       Impact factor: 16.971

Review 5.  Structure and function of helix-loop-helix proteins.

Authors:  C Murre; G Bain; M A van Dijk; I Engel; B A Furnari; M E Massari; J R Matthews; M W Quong; R R Rivera; M H Stuiver
Journal:  Biochim Biophys Acta       Date:  1994-06-21

6.  Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.

Authors:  Naoyuki Umetani; Hiroya Takeuchi; Akihide Fujimoto; Masaru Shinozaki; Anton J Bilchik; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

7.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

8.  Id4, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiation.

Authors:  Yoshimi Tokuzawa; Ken Yagi; Yzumi Yamashita; Yutaka Nakachi; Itoshi Nikaido; Hidemasa Bono; Yuichi Ninomiya; Yukiko Kanesaki-Yatsuka; Masumi Akita; Hiromi Motegi; Shigeharu Wakana; Tetsuo Noda; Fred Sablitzky; Shigeki Arai; Riki Kurokawa; Toru Fukuda; Takenobu Katagiri; Christian Schönbach; Tatsuo Suda; Yosuke Mizuno; Yasushi Okazaki
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

9.  Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.

Authors:  H Taniguchi; F V Jacinto; A Villanueva; A F Fernandez; H Yamamoto; F J Carmona; S Puertas; V E Marquez; Y Shinomura; K Imai; M Esteller
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

10.  Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B.

Authors:  Pankaj Sharma; Divya Patel; Jaideep Chaudhary
Journal:  Cancer Med       Date:  2012-08-28       Impact factor: 4.452

View more
  15 in total

1.  Induction of Lumen Formation in a Three-dimensional Model of Mammary Morphogenesis by Transcriptional Regulator ID4: ROLE OF CaMK2D IN THE EPIGENETIC REGULATION OF ID4 GENE EXPRESSION.

Authors:  Tung Nguyen; John E Shively
Journal:  J Biol Chem       Date:  2016-06-14       Impact factor: 5.157

2.  HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.

Authors:  Shujian Ge; Dan Wang; Beibei Lv; Shuping Yang; Chunmei Liu; Bin Xu; Chunming Zhao; Yejun Qin; Jiawen Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

3.  Id4 promotes cell proliferation in hepatocellular carcinoma.

Authors:  Yang Zhang; Li-Xing Zhang; Xiao-Qin Liu; Fang-Yu Zhao; Chao Ge; Tao-Yang Chen; Ming Yao; Jin-Jun Li
Journal:  Chin J Cancer       Date:  2017-02-01

4.  Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.

Authors:  Jugal Bharat Joshi; Divya Patel; Derrick J Morton; Pankaj Sharma; Jin Zou; Dhanushka Hewa Bostanthirige; Yamini Gorantla; Peri Nagappan; Shravan Kumar Komaragiri; Jeffrey C Sivils; Huan Xie; Ravi Palaniappan; Guangdi Wang; Marc B Cox; Jaideep Chaudhary
Journal:  Mol Oncol       Date:  2017-03-02       Impact factor: 6.603

5.  Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.

Authors:  Maxwell Korang-Yeboah; Divya Patel; Derrick Morton; Pankaj Sharma; Yamini Gorantla; Jugal Joshi; Perri Nagappan; Ravi Pallaniappan; Jaideep Chaudhary
Journal:  Oncotarget       Date:  2016-10-18

Review 6.  The Id-protein family in developmental and cancer-associated pathways.

Authors:  Cornelia Roschger; Chiara Cabrele
Journal:  Cell Commun Signal       Date:  2017-01-25       Impact factor: 5.712

7.  Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.

Authors:  Xiao-Ling Zhou; Yan-Hong Ye; Shu-Ming Sun; Xiao-Feng Lu; Wei-Quan Liang; Chun-Fa Chen; Hao-Yu Lin
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

8.  The Recombinant Inhibitor of DNA Binding Id2 Forms Multimeric Structures via the Helix-Loop-Helix Domain and the Nuclear Export Signal.

Authors:  Cornelia Roschger; Mario Schubert; Christof Regl; Ancuela Andosch; Augusto Marquez; Thomas Berger; Christian G Huber; Ursula Lütz-Meindl; Chiara Cabrele
Journal:  Int J Mol Sci       Date:  2018-04-07       Impact factor: 5.923

9.  Differential interactions between Notch and ID factors control neurogenesis by modulating Hes factor autoregulation.

Authors:  Marcelo Boareto; Dagmar Iber; Verdon Taylor
Journal:  Development       Date:  2017-10-01       Impact factor: 6.868

Review 10.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.